Vania Francois
Family · Rocky Mount, NCNPI 1184348740
Payments from drug & device makers
Across 134 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$305
- Novo Nordisk$297
- GSK$295
- AbbVie$253
- Amgen$208
- AstraZeneca$172
- plus $889 from 21 others
What the payments were for
- Food & beverage$2,420100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $305 |
| Novo Nordisk | 18 | $297 |
| GSK | 14 | $295 |
| AbbVie | 14 | $253 |
| Amgen | 13 | $208 |
| AstraZeneca(2 entities) | 10 | $172 |
| Bayer | 9 | $143 |
| Boehringer Ingelheim | 6 | $128 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| Pfizer | 4 | $68 |
| Merck | 3 | $57 |
| Eisai Inc. | 2 | $46 |
| Sanofi Pasteur Inc. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Exact Sciences | 2 | $35 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Grifols USA, LLC | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Corcept Therapeutics | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Organon | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$2,420 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 82 | $80,446 |
| OzempicSemaglutide | 45 | $72,631 |
| TrulicityDulaglutide | 25 | $41,793 |
| EliquisApixaban | 37 | $23,574 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $18,260 |
| FarxigaDapagliflozin Propanediol | 22 | $16,692 |
| JanuviaSitagliptin Phosphate | 25 | $15,695 |
| RybelsusSemaglutide | 11 | $14,211 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $10,642 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,066 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,512 |
| Dexlansoprazole DrDexlansoprazole | 24 | $3,372 |
| Atorvastatin Calcium | 173 | $1,820 |
| Amlodipine Besylate | 196 | $1,507 |
| Rosuvastatin Calcium | 111 | $1,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $297 | $86,84256 claims |
| Boehringer IngelheimJardiance | $128 | $80,44682 claims |
| Lilly USA, LLCTrulicity | $305 | $41,79325 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $172 | $29,27051 claims |
| PfizerEliquis | $68 | $23,57437 claims |
| GSKTrelegy Ellipta | $295 | $18,26019 claims |
| MerckJanuvia | $57 | $15,69525 claims |
| AbbVieSynthroid | $253 | $86911 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $62764 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.
Other family in Rocky Mount
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.